Recently analysts working for numerous investment brokerages have updated their research report ratings and price targets on shares of Cliffs Natural Resources Inc. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 250%.
Advertisement
Currently, the stock carries a price to earnings ratio of 9.24, a price to book ratio of 0, and a price to sales ratio of 0.72. During last trade, its maximum trading price was registered $5.90 and it’s the minimum trading price was noted $5.63.
Among the US-focused (DIA) iron ore miners, Cliffs Natural Resources (CLF) has “buy” ratings from 22% of the analysts covering the stock.
During the past 4 weeks, traders have been relatively bearish on Cliffs Natural Resources (CLF), hence the stock is down -29.25% when compared to the S&P 500 during the same period.
Price to sales ratio was lasted at 0.94. But it fell sharply on August 10 following management’s announcement that the company would price a share offering at a sharp discount to its current price. They are projecting Next Quarter growth of 228.6%.
07/12/2016 – Cliffs Natural Resources Inc. had its “overweight” rating reiterated by analysts at JP Morgan.
Oasis Petroleum Inc. (NYSE:OAS) now has mean rating of 2.3 while 9 analyst have recommended the shares as “BUY”, 6 commented as “OUTPERFORM” and 19 commented as “HOLD”. However, several analysts have revised their target prices for the stock. The analysts estimated mean EPS at 0.18 while the high and low EPS estimate stand at 0.34 and -0.08 respectively. With a one year target estimate of $13.15 and RSI of 76.4, the stock still has upside potential, making it a sell for now.
04/30/2015 – Cliffs Natural Resources Inc. had its “underperform” rating reiterated by analysts at Wolfe Research.
Cliffs Natural Resources (CLF) announced second quarter ended March 31, 2016 total revenue of $496.2 million, slightly below $498.1 million of consolidated revenue during the same period a year ago. The companys lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial.
Denbury Resources Inc has moved 1.78% above its 50-day simple moving average of $3.03 and went up 14.47% from its 200-day simple moving average of $3.20. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell The mean price target for the shares of company is at $11.91 while the highest price target suggested by the analysts is $18.00 and low price target is $5.00. The average volume stands around 12.86 million shares. P/E (price to earnings) ratio is 9.35 and Forward P/E ratio of 16.16.
The company shows its Return on Assets (ROA) value of 2.2%. While it’s Return on Investment (ROI) value is 0%. A look on the firm performance, its monthly performance is 15.58% and a quarterly performance of 27.00%.
Advertisement
Along with these its year to date performance is standing at 273.42%.
